8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.57%
Negative revenue growth while 3088.T stands at 4.54%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.27%
Negative gross profit growth while 3088.T is at 3.92%. Joel Greenblatt would examine cost competitiveness or demand decline.
-27.63%
Negative EBIT growth while 3088.T is at 27.73%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-30.80%
Negative operating income growth while 3088.T is at 7.30%. Joel Greenblatt would press for urgent turnaround measures.
-28.44%
Negative net income growth while 3088.T stands at 38.64%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-28.45%
Negative EPS growth while 3088.T is at 38.63%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-28.45%
Negative diluted EPS growth while 3088.T is at 62.86%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.76%
10Y revenue/share CAGR above 1.5x 3088.T's 13.28%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
86.76%
5Y revenue/share CAGR above 1.5x 3088.T's 13.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
54.48%
3Y revenue/share CAGR above 1.5x 3088.T's 15.46%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
206.94%
Net income/share CAGR above 1.5x 3088.T's 71.52% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
206.94%
5Y net income/share CAGR above 1.5x 3088.T's 71.52%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
61.89%
3Y net income/share CAGR above 1.5x 3088.T's 6.54%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
126.07%
Equity/share CAGR of 126.07% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
126.07%
Equity/share CAGR of 126.07% while 3088.T is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.28%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
6.72%
Asset growth above 1.5x 3088.T's 2.27%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.46%
BV/share growth above 1.5x 3088.T's 2.39%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-18.56%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.